Brief: Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
24/11/2021 13:23
Nov 24 (Reuters) - Seelos Therapeutics Inc SEEL.O :
* SEELOS THERAPEUTICS ANNOUNCES ACQUISITION OF AN EXCLUSIVE
LICENSE OF IX BIOPHARMA'S PROPRIETARY WAFER-BASED DELIVERY
PLATFORM FOR SUBLINGUAL KETAMINE
* SEELOS THERAPEUTICS INC - NEW SLS-003 PROGRAM EXTENDS
SEELOS'
KETAMINE FRANCHISE INTO ADDITIONAL INDICATIONS INCLUDING CHRONIC
NEUROPATHIC PAIN
* SEELOS THERAPEUTICS INC - SEELOS PLANS TO EVALUATE
SUBLINGUAL
KETAMINE, NOW NAMED SLS-003, IN PAIN INDICATIONS
* SEELOS THERAPEUTICS INC - PURSUANT TO LICENSE AGREEMENT,
SEELOS
WILL PAY IX BIOPHARMA A ONE-TIME, UPFRONT FEE OF $9 MILLION
Source text for Eikon: ID:nPn7sB5Xna
Further company coverage: SEEL.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Seelos Therapeutics
See all newsBrief: Seelos Therapeutics Commences Chapter 11 Proceedings- Court Filing
Brief: Seelos Therapeutics Announces Notice Of Delisting From Nasdaq And Transfer Of Listing To Over-The-Counter Market
Brief: Seelos Announces Postponement Of Its Annual Meeting Of Stockholders
Brief: Seelos Therapeutics Announces 1-For-16 Reverse Stock Split
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio